Patents by Inventor Scott Armstrong

Scott Armstrong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11523864
    Abstract: An electrosurgical controller and related methods. At least some of the illustrative embodiments are methods including: placing a distal end of an electrosurgical wand in operational relationship with biological tissue; delivering energy to an active electrode of the electrosurgical wand. During delivering energy, the method may comprise: measuring a value indicative of flow of the energy to the active electrode; summing, over a first predetermined window of time, to create a first value indicative of energy provided to the active electrode; summing, over a second predetermined window of time, to create a second value indicative of energy provided to the active electrode. The method may further comprise: ceasing delivering energy responsive to the first value meeting or exceeding a predetermined value; and ceasing delivering energy responsive to the second value meeting or exceeding a threshold value.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: December 13, 2022
    Assignee: ArthroCare Corporation
    Inventors: Jean Woloszko, Scott A. Armstrong, Michael Bozeman, Christopher A. Wallis
  • Patent number: 11525260
    Abstract: The disclosure presents a formwork system which utilizes Fiber Reinforced Polymer (FRP) panels to create modular segments to form and reinforce concrete subgrade structures. The segments may be rearranged and bonded together to conform to intended dimensions of many subgrade structures. The segments are manufactured by cast molding, bonding or vacuum forming. The segments may include integrated FRP stanchions to prevent deflection of the panels during concrete placement. The stanchions also may be used for positioning structural steel or FRP rebar. FRP bars are permanently bonded to the interior sides of the panels inside the segments. In use, the assembled segments are filled with concrete. After the concrete is cured, the segments remain in place and function as external protection and reinforcement for the cured concrete.
    Type: Grant
    Filed: November 10, 2020
    Date of Patent: December 13, 2022
    Assignee: Forma Technologies Inc.
    Inventor: Scott Armstrong
  • Publication number: 20220389023
    Abstract: Disclosed herein are compounds that target SMARCA2 and SMARCA4, causing their degradation. Also disclosed herein are compositions and methods of use in treating associated disorders and diseases.
    Type: Application
    Filed: June 25, 2020
    Publication date: December 8, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Jun Qi, Scott Armstrong, Lei Wu
  • Publication number: 20220343300
    Abstract: A financial institution agnostic saving system including a server configured to (i) receive information for a funding source of a user at a first financial institution; (ii) receive information for a saving account of the user at a second financial institution; (iii) receive user saving target information for the user which includes a saving rule for determining when to transfer funds from the funding source to the saving account wherein the saving rule is defined based on an amount spent by the user; (iv) receive transaction information for a transaction by the user from a third financial institution, wherein the transaction information includes the amount spent by the user; and (v) transfer money from the funding source to the saving account according to the saving rule. The system may include a marketplace which allows users to modify user saving target information and/or make purchases with savings.
    Type: Application
    Filed: April 22, 2022
    Publication date: October 27, 2022
    Inventors: Scott Armstrong, Ryan Armstrong
  • Publication number: 20220307031
    Abstract: The presently disclosed subject matter relates to the administration of a KMT2D inhibitor for the treatment of a cancer. The present invention is based on the discovery that upon PI3K inhibition, KMT2D activity is upregulated, resulting in an increase in the expression of genes involved in breast cancer cell proliferation and tumor growth. Accordingly, the present invention provides methods for treating a subject that has cancer by administering a therapeutically effective amount of an KMT2D inhibitor.
    Type: Application
    Filed: February 10, 2022
    Publication date: September 29, 2022
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Jose Baselga, Eneda Toska, Scott Armstrong
  • Patent number: 11369586
    Abstract: Described herein are antifungal peptoids, the development and characterization of the antifungal peptoids, methods of making the antifungal peptoids, and methods of using the antifungal peptoids. In some embodiments, the antifungal peptoids may be administered to a subject infected with or at risk of being infected with pathogenic fungi including, for example Cryptococcus spp. In some embodiments, the Cryptococcus spp. may include C. neoformans or C. gattii or both.
    Type: Grant
    Filed: December 18, 2019
    Date of Patent: June 28, 2022
    Assignee: Middle Tennessee State University
    Inventors: Kevin L. Bicker, Madyson P. Middleton, Scott A. Armstrong
  • Publication number: 20220145622
    Abstract: The disclosure presents a composite conduit formwork structure which includes a cylindrical outer casing adapted to bond with a cylindrical inner casing which are maintained at a fixed distance apart by a plurality of radial stanchions. The inner casing and outer casing form an interior void which is filled with concrete during manufacture. The outer casing and inner casing remain in place to protect the structure once completed. A novel method of assembly is also provided whereby radial stanchions are rotated between the outer casing and inner casing. All of the components in a preferred embodiment are formed of a fiberglass material.
    Type: Application
    Filed: November 10, 2020
    Publication date: May 12, 2022
    Applicant: Forma Technologies Inc.
    Inventor: Scott Armstrong
  • Publication number: 20220145621
    Abstract: The disclosure presents a composite column formwork which utilizes a fiber reinforced polymer (FRP) stay in place container which incorporates horizontally coplanar support chairs bonded to the interior surface, closed ties bonded to the support chairs and a plurality of longitudinal rebar enforcements bonded to the closed ties. All of the components in a preferred embodiment are formed of a fiberglass material.
    Type: Application
    Filed: November 10, 2020
    Publication date: May 12, 2022
    Applicant: Forma Technologies Inc.
    Inventor: Scott Armstrong
  • Publication number: 20220145620
    Abstract: The disclosure presents a formwork system which utilizes Fiber Reinforced Polymer (FRP) panels to create modular segments to form and reinforce concrete subgrade structures. The segments may be rearranged and bonded together to conform to intended dimensions of many subgrade structures. The segments are manufactured by cast molding, bonding or vacuum forming. The segments may include integrated FRP stanchions to prevent deflection of the panels during concrete placement. The stanchions also may be used for positioning structural steel or FRP rebar. FRP bars are permanently bonded to the interior sides of the panels inside the segments. In use, the assembled segments are filled with concrete. After the concrete is cured, the segments remain in place and function as external protection and reinforcement for the cured concrete.
    Type: Application
    Filed: November 10, 2020
    Publication date: May 12, 2022
    Applicant: Forma Technologies Inc.
    Inventor: Scott Armstrong
  • Publication number: 20220145647
    Abstract: The disclosure presents a reconfigurable composite floor formwork which defined by a plurality of interlocking fiberglass panels formed into profiles which may be moved and adapted to provide a concrete form for a floor or ceiling. All of the components in a preferred embodiment are formed of a fiberglass material.
    Type: Application
    Filed: November 10, 2020
    Publication date: May 12, 2022
    Applicant: Forma Technologies Inc.
    Inventor: Scott Armstrong
  • Publication number: 20220145646
    Abstract: The disclosure presents a composite concrete structure formwork which comprises stay in place fiberglass profiles and reinforcement to form various building and shelter structures. The structures include an interior container maintained at a set distance within an exterior container to form a void. The void is filled with wet concrete which is allowed to cure. All of the components in a preferred embodiment are formed of a fiberglass material.
    Type: Application
    Filed: November 10, 2020
    Publication date: May 12, 2022
    Applicant: Forma Technologies Inc.
    Inventor: Scott Armstrong
  • Publication number: 20220048942
    Abstract: Provided herein are bifunctional compounds with a moiety or domain that is a binder of the ubiquitin receptor RPN13 and another moiety or domain that is a binder of a target protein DOT1L to induce degradation of DOT1L. Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases, such as cancers). Provided also are methods of inducing the degradation of DOT1L by administering a bifunctional compound or composition described herein, wherein one domain of the bifunctional compound is a binder of the ubiquitin receptor RPN13 and another domain of the compound is a binder of the target protein DOT1L in a subject.
    Type: Application
    Filed: January 9, 2020
    Publication date: February 17, 2022
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Scott Armstrong, Jun Qi
  • Patent number: 11248229
    Abstract: The presently disclosed subject matter relates to the administration of a KMT2D inhibitor for the treatment of a cancer. The present invention is based on the discovery that upon PI3K inhibition, KMT2D activity is upregulated, resulting in an increase in the expression of genes involved in breast cancer cell proliferation and tumor growth. Accordingly, the present invention provides methods for treating a subject that has cancer by administering a therapeutically effective amount of an KMT2D inhibitor.
    Type: Grant
    Filed: May 10, 2019
    Date of Patent: February 15, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Jose Baselga, Eneda Toska, Scott Armstrong
  • Publication number: 20210379078
    Abstract: This invention is based on the discovery that inhibiting more than one pathway in senescent cells leading to apoptosis has a profound effect: namely, increasing the potency or the cell specificity of the therapy. Combining a Bcl inhibitor with an Mcl 1 inhibitor increases the ability of the Bcl inhibitor to remove senescent cells from the site of an adverse condition synergistically. This increases the types of senescent cells that can be targeted, broadens the therapeutic range, and allows the user to tailor a particular combination of agents by adjusting the molar ratio for the patient being treated. Suitable indications for treatment may include any condition thought to be mediated at least in part by senescent cells, such as ophthalmic conditions, pulmonary conditions, and atherosclerosis.
    Type: Application
    Filed: October 24, 2019
    Publication date: December 9, 2021
    Inventors: Pieter Bas Kwak, Scott Armstrong, Pedro Beltran, Anne-Marie Beausoleil
  • Publication number: 20210130386
    Abstract: Provided herein are bifunctional compounds with a moiety (e.g., lenalidomide, thalidomide) that is a binder of an E3 ubiquitin ligase (e.g., Cereblon) and another moiety that is a binder of a target protein DOT1L to induce degradation of DOT1L. Also provided are pharmaceutical compositions comprising the bifunctional compounds, and methods of treating and/or preventing diseases (e.g., proliferative diseases, such as cancers). Provided also are methods of inducing the degradation of DOT1L by administering a bifunctional compound or composition described herein, wherein one component of the bifunctional compound is a binder of an E3 ubiquitin ligase (e.g., lenalidomide, thalidomide) and another component of the compound is a binder of the target protein DOT1L in a subject.
    Type: Application
    Filed: June 27, 2019
    Publication date: May 6, 2021
    Applicant: DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Jun Qi, Scott Armstrong, Paul M. Park
  • Patent number: 10869868
    Abstract: Disclosed are methods for inhibiting proliferation of or inducing apoptosis in certain leukemia cells or both. The methods comprise contacting a leukemia cell exhibiting an NPM1 mutation with a pharmacologic inhibitor of interaction between MLL and menin. More broadly, disclosed are methods for treating a susceptible leukemia using pharmacologic inhibition of Menin-MLL interaction. Also disclosed are methods for treating such leukemias using inhibition of Menin-MLL interaction in combination with DOT1L inhibition.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: December 22, 2020
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventor: Scott A. Armstrong
  • Publication number: 20200354336
    Abstract: This invention is based on the discovery that many lung diseases associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The severity of age-related conditions typically correlates with the abundance of senescent cells: thus, clearing senescent cells can help abrogate the condition: providing symptomatic relief, and potentially inhibiting disease progression. In accordance with this invention, a family of Bcl protein inhibitors has been developed for the treatment of lung diseases. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable pulmonary diseases.
    Type: Application
    Filed: August 13, 2018
    Publication date: November 12, 2020
    Inventors: Nick Vlahakis, Scott Armstrong, Jamie Dananberg, Ryan Hudson, Anne-Marie Beausoleil, Nathaniel David, Remi-Martin Laberge
  • Publication number: 20200239963
    Abstract: Disclosed are: (i) methods for identifying leukemia patients who (or leukemia cells that) do not exhibit an MLL-translocation, rearrangement or MLL-partial tandem duplication but who are nonetheless susceptible to treatment with DOT1L inhibitors; and (ii) methods for treating leukemia patients who (or inhibiting proliferation or inducing apoptosis of leukemia cells that) do not exhibit an MLL-translocation, rearrangement or MLL-partial tandem duplication with DOT1L inhibitors. The patients identified as susceptible and the patients (or cells) treated exhibit elevated expression of a IIOX cluster gene or of a HOX cluster-associated gene. Elevated expression of such genes can be measured, e.g.
    Type: Application
    Filed: September 9, 2019
    Publication date: July 30, 2020
    Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventor: Scott A. ARMSTRONG
  • Publication number: 20200199103
    Abstract: This invention is based on the discovery that many lung diseases associated with aging are mediated at least in part by cells bearing a senescent phenotype. Senescent cells accumulate with age, and express factors that contribute to the pathophysiology of age related conditions. The severity of age-related conditions typically correlates with the abundance of senescent cells: thus, clearing senescent cells can help abrogate the condition: providing symptomatic relief, and potentially inhibiting disease progression. In accordance with this invention, a family of Bcl protein inhibitors has been developed for the treatment of lung diseases. These senolytic agents have an appropriate dose and specificity profile to be effective in the clinical management of previously intractable pulmonary diseases.
    Type: Application
    Filed: August 13, 2018
    Publication date: June 25, 2020
    Inventors: Nick Vlahakis, Scott Armstrong, Jamie Dananberg, Ryan Hudson, Anne-Marie Beausoleil, Nathaniel David, Remi-Martin Laberge
  • Publication number: 20200188354
    Abstract: Described herein are antifungal peptoids, the development and characterization of the antifungal peptoids, methods of making the antifungal peptoids, and methods of using the antifungal peptoids. In some embodiments, the antifungal peptoids may be administered to a subject infected with or at risk of being infected with pathogenic fungi including, for example Cryptococcus spp. In some embodiments, the Cryptococcus spp. may include C. neoformans or C. gattii or both.
    Type: Application
    Filed: December 18, 2019
    Publication date: June 18, 2020
    Inventors: Kevin L. Bicker, Madyson P. Middleton, Scott A. Armstrong